LinkedIn Profile

Access zPREDICTA historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:zpredicta 10663694 Mar 18th, 2023 12:00AM zPREDICTA, a Predictive Oncology company 750 2.00 Open Biotechnology Research Mar 18th, 2023 10:54PM Mar 18th, 2023 10:54PM Patient-derived 3D culture models enabling accurate efficacy testing of anticancer agents. zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic. Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications. Open preclinical drug testing, 3D culture, human microenviroment, and tumor microenviroment Open 5941 Optical Court San Jose CA US 95138 zPREDICTA
private:zpredicta 10663694 Mar 17th, 2023 12:00AM zPREDICTA, a Predictive Oncology company 750 2.00 Open Biotechnology Research Mar 17th, 2023 04:28PM Mar 17th, 2023 04:28PM Patient-derived 3D culture models enabling accurate efficacy testing of anticancer agents. zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic. Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications. Open preclinical drug testing, 3D culture, human microenviroment, and tumor microenviroment Open 5941 Optical Court San Jose CA US 95138 zPREDICTA
private:zpredicta 10663694 Mar 16th, 2023 12:00AM zPREDICTA, a Predictive Oncology company 749 2.00 Open Biotechnology Research Mar 16th, 2023 09:29PM Mar 16th, 2023 09:29PM Patient-derived 3D culture models enabling accurate efficacy testing of anticancer agents. zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic. Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications. Open preclinical drug testing, 3D culture, human microenviroment, and tumor microenviroment Open 5941 Optical Court San Jose CA US 95138 zPREDICTA
private:zpredicta 10663694 Mar 15th, 2023 12:00AM zPREDICTA, a Predictive Oncology company 749 2.00 Open Biotechnology Research Mar 15th, 2023 06:33PM Mar 15th, 2023 06:33PM Patient-derived 3D culture models enabling accurate efficacy testing of anticancer agents. zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic. Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications. Open preclinical drug testing, 3D culture, human microenviroment, and tumor microenviroment Open 5941 Optical Court San Jose CA US 95138 zPREDICTA
private:zpredicta 10663694 Mar 14th, 2023 12:00AM zPREDICTA, a Predictive Oncology company 749 2.00 Open Biotechnology Research Mar 14th, 2023 06:49PM Mar 14th, 2023 06:49PM Patient-derived 3D culture models enabling accurate efficacy testing of anticancer agents. zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic. Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications. Open preclinical drug testing, 3D culture, human microenviroment, and tumor microenviroment Open 5941 Optical Court San Jose CA US 95138 zPREDICTA
private:zpredicta 10663694 Mar 13th, 2023 12:00AM zPREDICTA, a Predictive Oncology company 749 2.00 Open Biotechnology Research Mar 13th, 2023 09:08PM Mar 13th, 2023 09:08PM Patient-derived 3D culture models enabling accurate efficacy testing of anticancer agents. zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic. Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications. Open preclinical drug testing, 3D culture, human microenviroment, and tumor microenviroment Open 5941 Optical Court San Jose CA US 95138 zPREDICTA
private:zpredicta 10663694 Mar 13th, 2023 12:00AM zPREDICTA, a Predictive Oncology company 749 2.00 Open Biotechnology Research Mar 13th, 2023 09:08PM Mar 13th, 2023 09:08PM Patient-derived 3D culture models enabling accurate efficacy testing of anticancer agents. zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic. Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications. Open preclinical drug testing, 3D culture, human microenviroment, and tumor microenviroment Open 5941 Optical Court San Jose CA US 95138 zPREDICTA
private:zpredicta 10663694 Mar 12th, 2023 12:00AM zPREDICTA, a Predictive Oncology company 749 2.00 Open Biotechnology Research Mar 12th, 2023 06:57PM Mar 12th, 2023 06:57PM Patient-derived 3D culture models enabling accurate efficacy testing of anticancer agents. zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic. Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications. Open preclinical drug testing, 3D culture, human microenviroment, and tumor microenviroment Open 5941 Optical Court San Jose CA US 95138 zPREDICTA
private:zpredicta 10663694 Mar 11th, 2023 12:00AM zPREDICTA, a Predictive Oncology company 749 2.00 Open Biotechnology Research Mar 11th, 2023 08:44PM Mar 11th, 2023 08:44PM Patient-derived 3D culture models enabling accurate efficacy testing of anticancer agents. zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic. Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications. Open preclinical drug testing, 3D culture, human microenviroment, and tumor microenviroment Open 5941 Optical Court San Jose CA US 95138 zPREDICTA
private:zpredicta 10663694 Mar 10th, 2023 12:00AM zPREDICTA, a Predictive Oncology company 749 2.00 Open Biotechnology Research Mar 11th, 2023 08:28AM Mar 11th, 2023 08:28AM Patient-derived 3D culture models enabling accurate efficacy testing of anticancer agents. zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic. Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications. Open preclinical drug testing, 3D culture, human microenviroment, and tumor microenviroment Open 5941 Optical Court San Jose CA US 95138 zPREDICTA

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.